Start Over

ASCO 2020.

Authors :: Bartsch R
Dieras V
Cortes J
Müller V
Ruhstaller T
Source :: Breast care (Basel, Switzerland) [Breast Care (Basel)] 2020 Aug; Vol. 15 (4), pp. 433-436. Date of Electronic Publication: 2020 Jul 16.
Publication Year :: 2020
Abstract: Competing Interests: Rupert Bartsch: advisory role in Astra-Zeneca, Celgene, Daiichi, Eisai, Eli-Lilly, MSD, Novartis, Pfizer, Pierre-Fabre, Puma, Roche, and Samsung; lecture honoraria from Accord, Astra-Zeneca, BMS, Celgene, Eli-Lilly, Novartis, Pfizer, Pierre-Fabre, Roche, and Sandoz; and research support from Daiichi, MSD, Novartis, and Roche. Veronique Dieras: consultant/advisory board for Roche/Genentech, Novartis, Lilly, Pfizer, AstraZeneca, Eisai, AbbVie, MSD, Daiichi Sankyo, and Seattle Genetics. Javier Cortes: consulting/advisor for Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, and Kyowa Kirin; honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme, and Daiichi Sankyo; research funding to the institution from Roche, Ariad Pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffmann-La Roche, Guardanth Health, Merck Sharp & Dohme, Pfizer, Piqur Therapeutics, Puma C, and Queen Mary University of London; and stock, patents, and intellectual property from MedSIR. Volkmar Müller: consultant for Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, ClinSol, Novartis, MSD, Daiichi-Sankyo, Eisai, Lilly, Tesaro, and Seattle Genetics and Nektar; and institutional research support from Novartis, Roche, Seattle Genetics, and Genentech. Thomas Ruhstaller: consultant/advisory boards for Roche/Genentech, Novartis, Lilly, and AstraZeneca.